The Trump administration announced Thursday new proposals that would ban what it calls “backdoor rebates,” as it seeks to lower drug costs for consumers at the pharmacy counter, a move that could impact the way insurers negotiate discounts on pharmaceuticals from manufacturers.
Democratic leaders sent letters Wednesday to three major pharmaceutical companies asking for the “root causes” of rising insulin costs, the latest attempt by Democrats to tackle high health-care costs in the U.S.
This is a Kaiser Health news story. For the first time since passing the Affordable Care Act, Democrats will soon control the House of Representatives and its powerful health committees. But Republicans’ tightened grip on the Senate means those hoping for another round of dramatic, progressive reforms may be disappointed. Empowered by voters outraged over… Read More »